Holen Sie sich die Stockscreener-App
29.01
8.04%
2.16
Handel nachbörslich:
29.03
0.02
+0.07%
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short Interest - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market - Investing.com
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market By Investing.com - Investing.com South Africa
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - AOL
Brokers Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Beam Therapeutics announces new data from BEACON Phase 1/2 trial of BEAM-101 - MSN
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up - MSN
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers - MSN
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Beam Therapeutics shares hold Outperform amid clinical data By Investing.com - Investing.com Canada
Beam Therapeutics shares hold Outperform amid clinical data - Investing.com
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell - TipRanks
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up - News & Insights
Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data - StockTitan
Beam Therapeutics Presents New Non-human Primate (NHP) Data - GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6%Here's Why - MarketBeat
BEAMBeam Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024 - Marketscreener.com
Beam Therapeutics Names Sravan K. Emany as CFO - TipRanks
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - The Manila Times
Beam Therapeutics Names Former Ironwood CFO & Banking Veteran Sravan Emany as New Finance Chief - StockTitan
Tom Jede - The Business Journals
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? - Yahoo Finance
Redmile Group LLC Has $39.47 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics adds Merck executive to board By Investing.com - Investing.com Canada
Erste Asset Management GmbH Makes New $544,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Fmr LLC - MarketBeat
Beam Therapeutics Inc. Announces the Appointment of Chirfi Guindo to Its Board of Directors - Marketscreener.com
Beam Therapeutics adds Merck executive to board - Investing.com
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - The Manila Times
Beam Therapeutics Expands its Board of Directors with - GlobeNewswire
Beam Therapeutics Strengthens Board with Merck's Chief Marketing Officer Chirfi Guindo - StockTitan
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Walleye Capital LLC Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Trading Report - Stock Traders Daily
20,892 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Intech Investment Management LLC - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):